KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Resmed (RMD) Other Non Operating Income (2016 - 2025)

Resmed's Other Non Operating Income history spans 17 years, with the latest figure at -$5.3 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 338.36% year-over-year to -$5.3 million; the TTM value through Dec 2025 reached -$14.2 million, down 149.44%, while the annual FY2025 figure was -$5.3 million, 50.43% down from the prior year.
  • Other Non Operating Income reached -$5.3 million in Q4 2025 per RMD's latest filing, down from -$3.8 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $4.7 million in Q1 2021 to a low of -$5.3 million in Q4 2025.
  • Average Other Non Operating Income over 5 years is -$831050.0, with a median of -$1.2 million recorded in 2022.
  • The largest YoY upside for Other Non Operating Income was 423.03% in 2024 against a maximum downside of 4947.54% in 2024.
  • A 5-year view of Other Non Operating Income shows it stood at $841000.0 in 2021, then tumbled by 302.97% to -$1.7 million in 2022, then soared by 59.81% to -$686000.0 in 2023, then surged by 423.03% to $2.2 million in 2024, then tumbled by 338.36% to -$5.3 million in 2025.
  • Per Business Quant, the three most recent readings for RMD's Other Non Operating Income are -$5.3 million (Q4 2025), -$3.8 million (Q3 2025), and -$979000.0 (Q2 2025).